Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1975 3
1978 2
1979 1
1980 2
1981 2
1983 2
1984 1
1986 2
1987 1
1988 2
1989 6
1990 6
1991 5
1992 2
1993 3
1994 3
1995 5
1996 8
1997 9
1998 3
1999 5
2000 8
2001 9
2002 18
2003 14
2004 9
2005 27
2006 25
2007 19
2008 26
2009 23
2010 38
2011 47
2012 36
2013 56
2014 57
2015 75
2016 79
2017 76
2018 85
2019 95
2020 109
2021 126
2022 114
2023 114
2024 40

Text availability

Article attribute

Article type

Publication date

Search Results

1,209 results

Results by year

Filters applied: . Clear all
Page 1
Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.
Maurer MJ, Ghesquières H, Jais JP, Witzig TE, Haioun C, Thompson CA, Delarue R, Micallef IN, Peyrade F, Macon WR, Jo Molina T, Ketterer N, Syrbu SI, Fitoussi O, Kurtin PJ, Allmer C, Nicolas-Virelizier E, Slager SL, Habermann TM, Link BK, Salles G, Tilly H, Cerhan JR. Maurer MJ, et al. J Clin Oncol. 2014 Apr 1;32(10):1066-73. doi: 10.1200/JCO.2013.51.5866. Epub 2014 Feb 18. J Clin Oncol. 2014. PMID: 24550425 Free PMC article. Clinical Trial.
Patient outcomes were evaluated at diagnosis and in the subsets of patients achieving event-free status at 12 months (EFS12) and 24 months (EFS24) from diagnosis. Overall survival was compared with age- and sex-matched population data. ...RESULTS: In all, 767 patien …
Patient outcomes were evaluated at diagnosis and in the subsets of patients achieving event-free status at 12 months (EFS12) and 24 …
Effect of a smartphone intervention as a secondary prevention for use among university students with unhealthy alcohol use: randomised controlled trial.
Bertholet N, Schmutz E, Studer J, Adam A, Gmel G, Cunningham JA, McNeely J, Daeppen JB. Bertholet N, et al. BMJ. 2023 Aug 16;382:e073713. doi: 10.1136/bmj-2022-073713. BMJ. 2023. PMID: 37586742 Free PMC article. Clinical Trial.
Additional outcomes were maximum number of drinks consumed on one occasion, alcohol related consequences, and academic performance. Follow-up assessments occurred at months three, six, and 12. Data were analysed by intention to treat and by using generalised linear mixed m …
Additional outcomes were maximum number of drinks consumed on one occasion, alcohol related consequences, and academic performance. Follow-u …
Ceftriaxone compared with benzylpenicillin in the treatment of neurosyphilis in France: a retrospective multicentre study.
Bettuzzi T, Jourdes A, Robineau O, Alcaraz I, Manda V, Molina JM, Mehlen M, Cazanave C, Tattevin P, Mensi S, Terrier B, Régent A, Ghosn J, Charlier C, Martin-Blondel G, Dupin N. Bettuzzi T, et al. Lancet Infect Dis. 2021 Oct;21(10):1441-1447. doi: 10.1016/S1473-3099(20)30857-4. Epub 2021 May 26. Lancet Infect Dis. 2021. PMID: 34051142
The primary outcome was the overall clinical response (ie, proportion of patients with a complete or partial response) 1 month after treatment initiation. The secondary endpoints were proportions of patients with a complete response at 1 month and serological respon …
The primary outcome was the overall clinical response (ie, proportion of patients with a complete or partial response) 1 month after …
Current Treatment of Melanoma Brain Metastases.
Nowacka A, Fajkiel-Madajczyk A, Ohla J, Woźniak-Dąbrowska K, Liss S, Gryczka K, Smuczyński W, Ziółkowska E, Bożiłow D, Śniegocki M, Wiciński M. Nowacka A, et al. Cancers (Basel). 2023 Aug 14;15(16):4088. doi: 10.3390/cancers15164088. Cancers (Basel). 2023. PMID: 37627116 Free PMC article. Review.
Before discovering new methods of treating metastases, the overall survival of patients with this disease was 6 months. Currently, research is being conducted on new drugs using immunotherapy (immune checkpoint inhibitors: anti-PD-1, anti-CTLA-4) and targeted therapy (BRAF …
Before discovering new methods of treating metastases, the overall survival of patients with this disease was 6 months. Currently, re …
Periodontitis induced by Porphyromonas gingivalis drives periodontal microbiota dysbiosis and insulin resistance via an impaired adaptive immune response.
Blasco-Baque V, Garidou L, Pomié C, Escoula Q, Loubieres P, Le Gall-David S, Lemaitre M, Nicolas S, Klopp P, Waget A, Azalbert V, Colom A, Bonnaure-Mallet M, Kemoun P, Serino M, Burcelin R. Blasco-Baque V, et al. Gut. 2017 May;66(5):872-885. doi: 10.1136/gutjnl-2015-309897. Epub 2016 Feb 2. Gut. 2017. PMID: 26838600 Free PMC article.
The mice were then fed with a diabetogenic/non-obesogenic fat-enriched diet for up to 3 months. Alveolar bone loss, periodontal microbiota dysbiosis and features of glucose metabolism were quantified. ...A treatment with inactivated Pg prior to the periodontal infection in …
The mice were then fed with a diabetogenic/non-obesogenic fat-enriched diet for up to 3 months. Alveolar bone loss, periodontal micro …
Marshall bundle elimination, Pulmonary vein isolation, and Line completion for ANatomical ablation of persistent atrial fibrillation (Marshall-PLAN): Prospective, single-center study.
Derval N, Duchateau J, Denis A, Ramirez FD, Mahida S, André C, Krisai P, Nakatani Y, Kitamura T, Takigawa M, Chauvel R, Tixier R, Pillois X, Sacher F, Hocini M, Haïssaguerre M, Jaïs P, Pambrun T. Derval N, et al. Heart Rhythm. 2021 Apr;18(4):529-537. doi: 10.1016/j.hrthm.2020.12.023. Epub 2020 Dec 29. Heart Rhythm. 2021. PMID: 33383226
METHODS: Left atrial (LA) sites were sequentially targeted as follows: (1) coronary sinus and vein of Marshall (CS-VOM) musculature; (2) PVI; and (3) anatomical isthmuses (mitral, roof, and cavotricuspid isthmus [CTI]). The primary endpoint was 12-month freedom from AF/atr …
METHODS: Left atrial (LA) sites were sequentially targeted as follows: (1) coronary sinus and vein of Marshall (CS-VOM) musculature; (2) PVI …
Immunotherapies Targeting Amyloid and Tau Protein in Alzheimer's Disease: Should We Move Away from Diseases and Focus on Biological Targets? A Systematic Review and Expert Opinion.
Esquer A, Blanc F, Collongues N. Esquer A, et al. Neurol Ther. 2023 Dec;12(6):1883-1907. doi: 10.1007/s40120-023-00541-1. Epub 2023 Oct 9. Neurol Ther. 2023. PMID: 37812325 Free PMC article. Review.
Three drugs (lecanemab, donanemab and aducanumab) are on track to be marketed in the coming months. In this systematic review, we review all Phase 2 and Phase 3 clinical trials conducted in this indication and the particularities of the molecules tested. ...
Three drugs (lecanemab, donanemab and aducanumab) are on track to be marketed in the coming months. In this systematic review, we rev …
Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study.
Boissel N, Chiaretti S, Papayannidis C, Ribera JM, Bassan R, Sokolov AN, Alam N, Brescianini A, Pezzani I, Kreuzbauer G, Zugmaier G, Foà R, Rambaldi A. Boissel N, et al. Blood Cancer J. 2023 Jan 4;13(1):2. doi: 10.1038/s41408-022-00766-7. Blood Cancer J. 2023. PMID: 36599847 Free PMC article.
Median overall survival (OS) was not reached over a median follow-up time of 18.5 months (Ph-, 18.8 [range: 5.1-34.8] months; Ph+, 16.5 [range: 1.8-31.6] months). In the R/R group, within two cycles of blinatumomab, 51% of Ph- and 41% of Ph+ patients achieved …
Median overall survival (OS) was not reached over a median follow-up time of 18.5 months (Ph-, 18.8 [range: 5.1-34.8] months; …
Non-hip/non-vertebral fractures - How to treat best?
Hoffmeyer P, Miozzari H, Holzer N. Hoffmeyer P, et al. Best Pract Res Clin Rheumatol. 2019 Apr;33(2):236-263. doi: 10.1016/j.berh.2019.03.019. Epub 2019 May 16. Best Pract Res Clin Rheumatol. 2019. PMID: 31547981 Review.
Non-displaced fractures around the foot may be treated with immobilisation and avoidance of full weight-bearing. As a rule, fractures take four months for consolidation. Individually tailored solutions are needed for frail patients with comorbidities. ...
Non-displaced fractures around the foot may be treated with immobilisation and avoidance of full weight-bearing. As a rule, fractures take f …
Pre-hospital thrombolysis in perspective.
Danchin N, Durand E, Blanchard D. Danchin N, et al. Eur Heart J. 2008 Dec;29(23):2835-42. doi: 10.1093/eurheartj/ehn462. Epub 2008 Oct 23. Eur Heart J. 2008. PMID: 18948355 Review.
Current treatment options, including the timely use of pre-hospital fibrinolysis, have reduced the overall 1 month mortality. Mortality can be further improved when patient characteristics, risk factors and time delays to treatment are considered. ...
Current treatment options, including the timely use of pre-hospital fibrinolysis, have reduced the overall 1 month mortality. Mortali …
1,209 results